Trials / Conditions / Newly Diagnosed Glioblastoma

Newly Diagnosed Glioblastoma

24 registered clinical trials studyying Newly Diagnosed Glioblastoma — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EG NCT07326566	Black Diamond Therapeutics, Inc.	Phase 2
Not Yet Recruiting	BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma NCT04903795	Mustafa Khasraw, MBChB, MD, FRCP, FRACP	Phase 1
Not Yet Recruiting	Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma NCT07346144	Trogenix ltd	Phase 1 / Phase 2
Recruiting	Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab NCT06816927	Duke University	Phase 2
Recruiting	Anterior Temporal Lobectomy in Temporal Glioblastoma NCT07021339	University Hospital, Bonn	Phase 3
Recruiting	New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study NCT06622434	Assistance Publique - Hôpitaux de Paris	Phase 1 / Phase 2
Recruiting	Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma NCT05380349	Swedish Medical Center	EARLY_Phase 1
Recruiting	Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma NCT05864534	Northwestern University	Phase 2
Unknown	A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 NCT04967690	Double Bond Pharmaceutical AB	Phase 1
Recruiting	The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab NCT05235737	Medical University of Silesia	Phase 4
Unknown	SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) NCT05163080	MimiVax, LLC	Phase 2
Unknown	Phase 2 Study of CAN008 in Subjects With GBM NCT05447195	CANbridge Life Sciences Ltd.	Phase 2
Unknown	Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma NCT04840069	St. Joseph's Hospital and Medical Center, Phoenix	Phase 2
Completed	Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma NCT04474353	Stanford University	Phase 1
Active Not Recruiting	A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma NCT04600817	TJ Biopharma Co., Ltd.	Phase 2
Active Not Recruiting	Pembrolizumab for Newly Diagnosed Glioblastoma NCT03899857	University of Zurich	Phase 2
Active Not Recruiting	Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma NCT04477200	University of Michigan Rogel Cancer Center	Phase 1
Active Not Recruiting	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279	Sapience Therapeutics	Phase 1 / Phase 2
Withdrawn	Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Gli NCT04065087	Genexine, Inc.	Phase 1 / Phase 2
Completed	Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma NCT03782415	MediciNova	Phase 1 / Phase 2
Completed	A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma NCT03345095	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3
Completed	Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma NCT03619239	Genexine, Inc.	Phase 1
Unknown	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed G NCT03400917	Aivita Biomedical, Inc.	Phase 2
Completed	Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma NCT01805453	Assistance Publique - Hôpitaux de Paris	Phase 3